PET-Specific Parameters and Radiotracers in Theoretical Tumour Modelling

The innovation of computational techniques serves as an important step toward optimized, patient-specific management of cancer. In particular, in silico simulation of tumour growth and treatment response may eventually yield accurate information on disease progression, enhance the quality of cancer treatment, and explain why certain therapies are effective where others are not. In silico modelling is demonstrated to considerably benefit from information obtainable with PET and PET/CT. In particular, models have successfully integrated tumour glucose metabolism, cell proliferation, and cell oxygenation from multiple tracers in order to simulate tumour behaviour. With the development of novel radiotracers to image additional tumour phenomena, such as pH and gene expression, the value of PET and PET/CT data for use in tumour models will continue to grow. In this work, the use of PET and PET/CT information in in silico tumour models is reviewed. The various parameters that can be obtained using PET and PET/CT are detailed, as well as the radiotracers that may be used for this purpose, their utility, and limitations. The biophysical measures used to quantify PET and PET/CT data are also described. Finally, a list of in silico models that incorporate PET and/or PET/CT data is provided and reviewed.

[1]  A. Scott,et al.  Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. , 2007, Seminars in nuclear medicine.

[2]  Jin Mo Goo,et al.  False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases , 2006, Korean journal of radiology.

[3]  Cyrill Burger,et al.  Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Daniela Thorwarth,et al.  A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia , 2005, Physics in medicine and biology.

[5]  Badreddine Bencherif,et al.  18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  P. Tracqui,et al.  Biophysical models of tumour growth , 2009 .

[7]  Vittorio Cristini,et al.  Multiscale cancer modeling. , 2010, Annual review of biomedical engineering.

[8]  P. Maini,et al.  The role of acidity in solid tumour growth and invasion. , 2005, Journal of theoretical biology.

[9]  Robert Jeraj,et al.  Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data , 2012, Physics in medicine and biology.

[10]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[11]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[12]  E Bezak,et al.  Efficient Monte Carlo modelling of individual tumour cell propagation for hypoxic head and neck cancer , 2008, Physics in medicine and biology.

[13]  Keigo Endo,et al.  Additional value of integrated PET/CT over PET alone in the initial staging and follow up of head and neck malignancy , 2010, Annals of nuclear medicine.

[14]  John L. Humm,et al.  Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging , 2008, Physics in medicine and biology.

[15]  A. Scarsbrook,et al.  False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. , 2011, Clinical radiology.

[16]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[17]  Heiko Schöder,et al.  Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. , 2009, Seminars in nuclear medicine.

[18]  David A. Mankoff,et al.  Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol , 2008, Journal of Nuclear Medicine.

[19]  Robert Jeraj,et al.  An imaging-based stochastic model for simulation of tumour vasculature , 2012, Physics in medicine and biology.

[20]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[21]  Roland Bares,et al.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  H. Frieboes,et al.  Predictive oncology: A review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth , 2007, NeuroImage.

[23]  G. V. von Schulthess,et al.  Why most PET of lung and head-and-neck cancer will be PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  W. De Wever,et al.  Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT , 2006, European Radiology.

[25]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  H. Frieboes,et al.  Nonlinear modelling of cancer: bridging the gap between cells and tumours , 2010, Nonlinearity.

[27]  F Dehdashti,et al.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[28]  Horst Kessler,et al.  Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.

[29]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Buck,et al.  PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  Tinsu Pan,et al.  Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. , 2006, AJR. American journal of roentgenology.

[32]  Jean-Claude Liehn,et al.  Positron Emission Tomography in oncology: present and future of PET and PET/CT. , 2009, Critical reviews in oncology/hematology.

[33]  M J Welch,et al.  Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[35]  Alfred A Bartolucci,et al.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.

[36]  Y Yonekura,et al.  Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  Stephan K. Haerle,et al.  Contrast‐enhanced 18F‐FDG‐PET/CT for the assessment of necrotic lymph node metastases , 2010, Head & neck.

[39]  Stefano Fanti,et al.  18F-DOPA PET and PET/CT , 2007, Journal of Nuclear Medicine.

[40]  Robert Jeraj,et al.  Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.

[41]  Kieran Smallbone,et al.  Mathematical modelling of tumour acidity. , 2008, Journal of theoretical biology.

[42]  C. Meltzer,et al.  PET/CT: form and function. , 2007, Radiology.

[43]  Robert Jeraj,et al.  An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response , 2008, Physics in medicine and biology.

[44]  Tomio Inoue,et al.  Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study , 2011, Annals of nuclear medicine.

[45]  Federico Turkheimer,et al.  Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future , 2012, Molecular Imaging and Biology.

[46]  Christophe Van de Wiele,et al.  Molecular imaging of hypoxia with radiolabelled agents , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  William M. Wells,et al.  Medical Image Computing and Computer-Assisted Intervention — MICCAI’98 , 1998, Lecture Notes in Computer Science.

[48]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[49]  Ora Israel,et al.  Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  Michael Brady,et al.  A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data , 2006, Physics in medicine and biology.

[51]  Leyun Pan,et al.  Shortened Acquisition Protocols for the Quantitative Assessment of the 2-Tissue-Compartment Model Using Dynamic PET/CT 18F-FDG Studies , 2011, The Journal of Nuclear Medicine.

[52]  Ronald M. Summers,et al.  Patient specific tumor growth prediction using multimodal images , 2014, Medical Image Anal..

[53]  Ronald M. Summers,et al.  Multimodal Image Driven Patient Specific Tumor Growth Modeling , 2013, MICCAI.

[54]  E. T. Gawlinski,et al.  Acid-mediated tumor invasion: a multidisciplinary study. , 2006, Cancer research.

[55]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[56]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[57]  A. Shields,et al.  PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  M. Spieth,et al.  A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  Yana K. Reshetnyak,et al.  Towards the improvement of an acidosis-targeting peptide PET tracer , 2012 .

[61]  Dan Grandér,et al.  How do mutated oncogenes and tumor suppressor genes cause cancer? , 1998, Medical oncology.

[62]  Michael A. Blake,et al.  Oral and IV contrast agents for the CT portion of PET/CT. , 2010, AJR. American journal of roentgenology.

[63]  Georgios Karanikas,et al.  Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  Tomio Inoue,et al.  Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[65]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  Yuichi Kimura,et al.  PET kinetic analysis—compartmental model , 2006, Annals of nuclear medicine.

[67]  Yana K Reshetnyak,et al.  A novel technology for the imaging of acidic prostate tumors by positron emission tomography. , 2009, Cancer research.

[68]  Ludwig G Strauss,et al.  Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[69]  Michael E. Phelps,et al.  Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.

[70]  John R. King,et al.  Vanishing beyond all orders: Stokes lines in a water-wave model equation , 2009 .

[71]  Christine Leininger,et al.  Van de Wiele , 2005 .

[72]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[73]  Robert J. Gillies,et al.  Tumor pH and Its Measurement , 2010, The Journal of Nuclear Medicine.